Desmoteplase for Acute Ischemic Stroke within 3 to 9 Hours after Symptom Onset: Evidence from Randomized Controlled Trials

about

Efficacy and safety of desmoteplase in acute ischemic stroke patients: A systematic review and meta-analysis.

P2860

Q33644102-1B16364F-DD72-4FD8-816A-45E996B3B116

P2860

Desmoteplase for Acute Ischemic Stroke within 3 to 9 Hours after Symptom Onset: Evidence from Randomized Controlled Trials

Item

http://www.wikidata.org/entity/Q36145434

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Desmoteplase for Acute Ischemi ...... m Randomized Controlled Trials

@ast

Desmoteplase for Acute Ischemi ...... m Randomized Controlled Trials

@en

type

Item

label

Desmoteplase for Acute Ischemi ...... m Randomized Controlled Trials

@ast

Desmoteplase for Acute Ischemi ...... m Randomized Controlled Trials

@en

prefLabel

Desmoteplase for Acute Ischemi ...... m Randomized Controlled Trials

@ast

Desmoteplase for Acute Ischemi ...... m Randomized Controlled Trials

@en

P1476

Desmoteplase for Acute Ischemi ...... m Randomized Controlled Trials

@en

P2093

Feng Liang

http://www.w3.org/2001/XMLSchema#string

Jianmin Zhang

http://www.w3.org/2001/XMLSchema#string

Jun Yu

http://www.w3.org/2001/XMLSchema#string

Keren Zhou

http://www.w3.org/2001/XMLSchema#string

Ligen Shi

http://www.w3.org/2001/XMLSchema#string

Yunping Li

http://www.w3.org/2001/XMLSchema#string

P2860

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Tissue plasminogen activator for acute ischemic stroke

Pretreatment diffusion- and perfusion-MR lesion volumes have a crucial influence on clinical response to stroke thrombolysis

Comparison of Therapeutic Effect of Recombinant Tissue Plasminogen Activator by Treatment Time after Onset of Acute Ischemic Stroke.

Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial.

Desmoteplase: discovery, insights and opportunities for ischaemic stroke.

Tissue Plasminogen Activator for preclinical stroke research: Neither "rat" nor "human" dose mimics clinical recanalization in a carotid occlusion model

Defining Core and Penumbra in Ischemic Stroke: A Voxel- and Volume-Based Analysis of Whole Brain CT Perfusion

The velocity of collateral filling predicts recanalization in acute ischemic stroke after intravenous thrombolysis.

Optimal Tmax threshold for predicting penumbral tissue in acute stroke

P2888

srep33989

P304

33989

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SREP33989

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Anwen Shao

P577

2016-09-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27671010

http://www.w3.org/2001/XMLSchema#string

P932

5037417

http://www.w3.org/2001/XMLSchema#string

Desmoteplase for Acute Ischemic Stroke within 3 to 9 Hours after Symptom Onset: Evidence from Randomized Controlled Trials

about

P2860

P2860

Desmoteplase for Acute Ischemic Stroke within 3 to 9 Hours after Symptom Onset: Evidence from Randomized Controlled Trials

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P478

P50

P577

P698

P932